HROWNasdaqPharmaceutical PreparationsFiscal year ends December 31
HARROW, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$27.68+0.40 (+1.47%)
Close on Oct 19, 2026
- Market cap
- $1.03B
- P/E (TTM)
- –
- Dividend yield
- –
HARROW, INC. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Branded | $56.11M | $30.70M | $74.12M | $51.58M | $42.27M | $27.78M | $46.34M | $28.55M | $27.36M | $13.87M | $16.40M | $14.50M | 79.4% | +32.7% |
| Compounding | $14.56M | $13.50M | – | $20.06M | $21.47M | $20.05M | – | $20.71M | $21.58M | $20.72M | – | – | 20.6% | -32.2% |
| ImprimisRx [Member] | – | – | $14.97M | $20.06M | $21.47M | $20.05M | $20.50M | $20.71M | $21.58M | $20.72M | $19.96M | $19.77M | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compounding | $344.00K | $343.00K | – | – | $6.43M | $4.96M | – | – | – | – | – | – | -94.7% |
| Branded | -$1.18M | -$11.63M | – | – | $10.82M | -$3.08M | – | – | – | – | – | – | -110.9% |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales, net | $70.57M | $44.13M | $89.01M | $71.50M | $63.66M | $47.75M | $66.22M | $49.02M | $48.87M | $34.51M | $35.64M | $31.81M | 99.9% | +10.9% |
| VEVYE | $29.39M | $20.95M | $25.91M | $22.63M | $18.64M | $21.52M | $15.96M | $5.19M | $4.32M | $2.60M | – | – | 41.6% | +57.6% |
| IHEEZO | $15.62M | $1.85M | $35.88M | $21.91M | $18.34M | $5.22M | $22.81M | $12.88M | $11.30M | $2.32M | $10.55M | $5.93M | 22.1% | -14.8% |
| Other branded products | $11.01M | $7.83M | $12.25M | $6.91M | $5.21M | $956.00K | $7.03M | $10.26M | $11.68M | $8.87M | $1.92M | $6.61M | 15.6% | +111.2% |
| Other revenues | $90.00K | $73.00K | $82.00K | $141.00K | $85.00K | $86.00K | $610.00K | $238.00K | $68.00K | $79.00K | $712.00K | $2.46M | 0.1% | +5.9% |
| Transfer Of Acquired Product Profit [Member] | – | – | – | – | – | – | – | – | – | – | – | $2.46M | – | – |
| Other Revenue [Member] | – | – | $82.00K | $141.00K | $85.00K | $86.00K | $540.00K | $228.00K | $68.00K | $79.00K | $2.16M | $1.96M | – | – |
By region
From the segment and revenue-disaggregation notes of Harrow's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.